Teicoplanin inhibits Ebola pseudovirus infection in cell culture
- 1 January 2016
- journal article
- Published by Elsevier in Antiviral Research
- Vol. 125, 1-7
Abstract
No abstract availableKeywords
Funding Information
- Institute Pasteur of Shanghai
- Chinese Academy of Sciences (2014004)
- National Natural Science Foundation of China (31400148)
- Chinese Academy of Sciences
This publication has 32 references indexed in Scilit:
- A screen of approved drugs and molecular probes identifies therapeutics with anti–Ebola virus activityScience Translational Medicine, 2015
- The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entryJournal of Antimicrobial Chemotherapy, 2014
- A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat AgentsPLOS ONE, 2013
- Teicoplanin therapy leading to a significant decrease in viral load in a patient with chronic hepatitis CJournal of Antimicrobial Chemotherapy, 2012
- An Analogue of the Antibiotic Teicoplanin Prevents Flavivirus Entry In VitroPLOS ONE, 2012
- Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibioticsJournal of Antimicrobial Chemotherapy, 2011
- Vancomycin vs teicoplanin in the treatment of Gram-positive infections: a pharmacoeconomic analysis in a Turkish University HospitalPharmacy World & Science, 2008
- Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibioticsAntiviral Research, 2006
- Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entryAntiviral Research, 2006
- Clinical Pharmacokinetics of TeicoplaninClinical Pharmacokinetics, 2000